Pα+ Psychedelic Bulletin #231 covers Compass’s 52-week psilocybin follow-up, Xylo’s Phase I trial, ibogaine policy, and industry news

This bulletin reports on major developments across psychedelic drug development, research, policy, and industry. Compass Pathways shared 52-week follow-up data from the open-label Part C of its COMP005 Phase 3 trial in treatment-resistant depression: about 70% of the 258 participants entered Part C, where eligible participants received another 25 mg dose of COMP360, and the company reported an average 13-point reduction from baseline in MADRS scores at Week 52 among those who had received the active dose in Part A. The bulletin also covers five training grant recipients, Xylo’s lead entering an Australian Phase I study, attorney Raúl Reichard’s discussion of Puerto Rico’s psychedelic research push, Eli Lilly’s acquisition of AtaiBeckley, and several ibogaine-related developments involving RFK Jr., Doug Collins, and an FDA citizen petition. It additionally examines whether “Arumaya” may be Usona’s planned psilocybin brand name.